Paper23082003
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM and 1 other. Clin Cancer Res, 2012. Cited by 340 papers, by iCite.
Cite this record
ConductScience Library. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Papers, record 23082003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23082003
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Endometrial Neoplasms | Major topic |
| Phosphatidylinositol 3-Kinases | Major topic |
| Proto-Oncogene Proteins c-akt | Major topic |
| Signal Transduction | Major topic |
| TOR Serine-Threonine Kinases | Major topic |
| Drug Therapy, Combination | |
| Enzyme Inhibitors | |
| Female | |
| Humans | |
| Phosphoinositide-3 Kinase Inhibitors |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| T32CA101642 | NIH |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) | Background | ClinicalTrials.gov | |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | Background | ClinicalTrials.gov |
Cited by229
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 340 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42922976 | Metabolic rewiring at the obesity-estrogen-polyamine axis in endometrial cancer: emerging mechanisms and translational opportunities. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42922976 | PubMed |
| 42886889 | PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/42886889 | PubMed |
| 42823426 | Efficacy of everolimus and letrozole with or without ribociclib in recurrent endometrial cancer: a phase 2 randomized clinical trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/42823426 | PubMed |
| 42795347 | Agmatine Sulfate Is Associated with Altered Redox Status, Apoptosis-Associated Responses, and AKT/JNK Signalling in Ishikawa Endometrial Cancer Cells. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42795347 | PubMed |
| 42793688 | Molecular Classification of Endometrial Cancer in the Era of Precision Oncology: Prognostic Significance, Emerging Biomarkers, and Personalized Therapeutic Strategies-A Systematic Review. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42793688 | PubMed |
| 42654474 | Exploring the Possible Role of Endometriosis-Associated Dysbiosis in Endometrial Carcinogenesis. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42654474 | PubMed |
| 42502277 | Effect of 6-gingerol on proliferation and apoptosis of ovarian cancer cells by the PI3K/AKT/mTOR pathway. | Biochem Biophys Rep | 2026 | https://conductscience.org/library/papers/42502277 | PubMed |
| 42449635 | Systemic Treatment Strategies Beyond Chemotherapy in Recurrent or Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449635 | PubMed |
| 42446810 | Transcriptomic analysis suggests FoxO and steroid hormone biosynthesis pathways are associated with 17α-methyltestosterone-induced partial masculinization in Trachinotus blochii. | Fish Physiol Biochem | 2026 | https://conductscience.org/library/papers/42446810 | PubMed |
| 42377597 | Emerging molecular targets in gynaecologic cancers: clinical implications for personalized therapy. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42377597 | PubMed |
| 42279419 | Redefining the Treatment Landscape of Advanced Endometrial Cancer in the Era of Immunotherapy and Precision Oncology. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279419 | PubMed |
| 42140194 | Artificial intelligence-driven integration of multi-biofluid omics and clinical phenotype enables stratification of endometrial cancer. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42140194 | PubMed |
| 42072404 | Metabolic Amplification in Endometrial Carcinogenesis: Biological Rationale and Translational Limits of Precision Chemoprevention. | Biomedicines | 2026 | https://conductscience.org/library/papers/42072404 | PubMed |
| 42022325 | Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance. | Front Oncol | 2026 | https://conductscience.org/library/papers/42022325 | PubMed |
| 41992249 | Single-cell and spatial transcriptomic analysis reveals PAX5's role and regulatory mechanisms in gastric adenocarcinoma lymph node metastasis. | J Transl Med | 2026 | https://conductscience.org/library/papers/41992249 | PubMed |
| 41886729 | Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/41886729 | PubMed |
| 41744888 | Endocrine Therapy for Endometrial Carcinoma: Current Evidence, Resistance Mechanisms, and Biomarker-Driven Patient Selection. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41744888 | PubMed |
| 41705240 | The dysregulation of the immune microenvironment during endometrial intraepithelial neoplasia serves as a marker of endometrial carcinogenesis. | Front Immunol | 2026 | https://conductscience.org/library/papers/41705240 | PubMed |
| 41682010 | FAM64A Potentiates Bladder Carcinoma Tumorigenesis and Metastasis Through PI3K/mTORC2/AKT Pathway Activation. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41682010 | PubMed |
| 41602366 | Development of a machine learning model for predicting the expression of proteins associated with targeted therapy in endometrial cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/41602366 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23082003
GET https://conductscience.org/api/papers/v1/23082003/cited_by?page=2